title: Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial.
abstract: BACKGROUND
  Cognitive behavioral therapy (CBT) and hypnotic medications are efficacious for short-term treatment of insomnia, but few patients achieve complete remission with any single treatment. It is unclear whether combined or maintenance therapies would enhance outcome.
  
  
  OBJECTIVE
  To evaluate the added value of medication over CBT alone for acute treatment of insomnia and the effects of maintenance therapies on long-term outcome.
  
  
  METHODS
  Prospective, randomized controlled trial involving 2-stage therapy for 160 adults with persistent insomnia treated at a university hospital sleep center in Canada between January 2002 and April 2005.
  
  
  METHODS
  Participants received CBT alone or CBT plus 10 mg/d (taken at bedtime) of zolpidem for an initial 6-week therapy, followed by extended 6-month therapy. Patients initially treated with CBT attended monthly maintenance CBT for 6 months or received no additional treatment and those initially treated with combined therapy (CBT plus 10 mg/d of zolpidem) continued with CBT plus intermittent use of zolpidem or CBT only.
  
  
  METHODS
  Sleep onset latency, time awake after sleep onset, total sleep time, and sleep efficiency derived from daily diaries (primary outcomes); treatment response and remission rates derived from the Insomnia Severity Index (secondary outcomes).
  
  
  RESULTS
  Cognitive behavioral therapy used singly or in combination with zolpidem produced significant improvements in sleep latency, time awake after sleep onset, and sleep efficiency during initial therapy (all P<.001); a larger increase of sleep time was obtained with the combined approach (P = .04). Both CBT alone and CBT plus zolpidem produced similar rates of treatment responders (60% [45/75] vs 61% [45/74], respectively; P = .84) and treatment remissions (39% [29/75] vs 44% [33/74], respectively; P = .52) with the 6-week acute treatment, but combined therapy produced a higher remission rate compared with CBT alone during the 6-month extended therapy phase and the 6-month follow-up period (56% [43/74 and 32/59] vs 43% [34/75 and 28/68]; P = .05). The best long-term outcome was obtained with patients treated with combined therapy initially, followed by CBT alone, as evidenced by higher remission rates at the 6-month follow-up compared with patients who continued to take zolpidem during extended therapy (68% [20/30] vs 42% [12/29]; P = .04).
  
  
  CONCLUSIONS
  In patients with persistent insomnia, the addition of medication to CBT produced added benefits during acute therapy, but long-term outcome was optimized when medication is discontinued during maintenance CBT.
  
  
  BACKGROUND
  clinicaltrials.gov Identifier: NCT00042146.
authors.affiliation: Université Laval, Ecole de Psychologie, Pavillon F A S, Québec, Québec, Canada G1K 0A6. cmorin@psy.ulaval.ca
authors.forename: Charles M
authors.initials: CM
authors.lastname: Morin
authors.forename: Annie
authors.initials: A
authors.lastname: Vallières
authors.forename: Bernard
authors.initials: B
authors.lastname: Guay
authors.forename: Hans
authors.initials: H
authors.lastname: Ivers
authors.forename: Josée
authors.initials: J
authors.lastname: Savard
authors.forename: Chantal
authors.initials: C
authors.lastname: Mérette
authors.forename: Célyne
authors.initials: C
authors.lastname: Bastien
authors.forename: Lucie
authors.initials: L
authors.lastname: Baillargeon
mesh_terms: D000368:Aged; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017286:Polysomnography; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D012890:Sleep; D007319:Sleep Initiation and Maintenance Disorders / Q000628:therapy*; D000077334:Zolpidem
chemical_list: D006993:Hypnotics and Sedatives; D011725:Pyridines; D000077334:Zolpidem